Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904722 | 0.98 | MEN1 (0.36) | ATMMAPTALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL11501574 | 0.84 | LMNA (0.36) | ATMALDH1A1TDP1SMN1; SMN2KDM4E | |
| SCHEMBL22996262 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL5858944 | 0.79 | KDM4E (0.43) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL5858718 | 0.79 | SIGMAR1 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL5857652 | 0.79 | GAA (0.36) | ALDH1A1 | |
| SCHEMBL9621298 | 0.78 | MEN1 (0.36) | ATMMAPTALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL12717852 | 0.77 | LMNA (0.38) | ATMALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL21076370 | 0.75 | CXCR4 (0.42) | ALDH1A1TDP1KDM4EMEN1KMT2A | |
| SCHEMBL21076379 | 0.75 | CXCR4 (0.39) | ALDH1A1KDM4EMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| CN-113493628-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1747210-A1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | ZIARCO INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005108384-A1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1593679-A1 | 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-0106055-B1 | PROCESS FOR THE PREPARATION OF CARBAMIC ACID ESTERS | BASF Aktiengesellschaft (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4537960-A | REACTING UREA WITH AN AMINOPROPANOL | BASF AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | disclosed |
| EP-0106055-A2 | Process for the preparation of carbamic acid esters | BASF Aktiengesellschaft (DE) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | HRH4, HRH3, TLR4 | ATM 2876/4885MAPT 2226/4885ALDH1A1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.